Search Results - "Raghav, P"

Clinical and molecular characterization of early‐onset colorectal cancer by Willauer, Alexandra N., Liu, Yusha, Pereira, Allan A. L., Lam, Michael, Morris, Jeffrey S., Raghav, Kanwal P. S., Morris, Van K., Menter, David, Broaddus, Russell, Meric‐Bernstam, Funda, Hayes‐Jordan, Andrea, Huh, Winston, Overman, Michael J., Kopetz, Scott, Loree, Jonathan M.

“…Background Colorectal cancer (CRC) incidence is increasing in adults younger than 50 years. This study evaluated clinical and molecular features to identify…”
Get full text

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial by Shroff, Rachna T, Javle, Milind M, Xiao, Lianchun, Kaseb, Ahmed O, Varadhachary, Gauri R, Wolff, Robert A, Raghav, Kanwal P S, Iwasaki, Michiko, Masci, Peter, Ramanathan, Ramesh K, Ahn, Daniel H, Bekaii-Saab, Tanios S, Borad, Mitesh J

“…Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and…”
Get more information

Front of pack labels enhance attention to nutrition information in novel and commercial brands by Becker, Mark W., Bello, Nora M., Sundar, Raghav P., Peltier, Chad, Bix, Laura

“…(1) To assess whether Front-of-Pack (FOP) nutrition labels garner attention more readily than more complete, mandated nutrition information (the Nutrition…”
Get full text

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes by RAGHAV, Kanwal P, WENTING WANG, SHUYING LIU, CHAVEZ-MACGREGOR, Mariana, XIAOLONG MENG, HORTOBAGYI, Gabriel N, MILLS, Gordon B, MERIC-BERNSTAM, Funda, BLUMENSCHEIN, George R, GONZALEZ-ANGULO, Ana M

“…To evaluate cMET (mesenchymal-epithelial transition factor gene) and phospho-cMET (p-cMET) levels in breast cancer subtypes and its impact on survival…”
Get full text

Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma by Yamashita, Suguru, Vauthey, Jean-Nicolas, Kaseb, Ahmed O., Aloia, Thomas A., Conrad, Claudius, Hassan, Manal M., Passot, Guillaume, Raghav, Kanwal P., Shama, Mohamed A., Chun, Yun Shin

“…Background Fibrolamellar carcinoma (FLC) and conventional hepatocellular carcinoma (HCC) share the same American Joint Committee on Cancer (AJCC) staging. The…”
Get full text

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology by Serpas, Victoria J, Raghav, Kanwal P, Halperin, Daniel M, Yao, James, Overman, Michael J

“…Clinical trials are an essential part of evidence-based medicine. Hence, to ensure transparency and accountability in these clinical trials, policies for…”
Get full text

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial by Raghav, Kanwal P, Stephen, Bettzy, Karp, Daniel D, Piha-Paul, Sarina A, Hong, David S, Jain, Dipti, Chudy Onwugaje, Dilichukwu O, Abonofal, Abdulrahman, Willett, Anneleis F, Overman, Michael, Smaglo, Brandon, Huey, Ryan W, Meric-Bernstam, Funda, Varadhachary, Gauri R, Naing, Aung

“…BackgroundCancer of unknown primary (CUP) is an aggressive rare malignancy with limited treatment options. Data regarding clinical activity of immune…”
Get full text

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers by Raghav, Kanwal P. S., Hernandez‐Aya, Leonel F., Lei, Xiudong, Chavez‐MacGregor, Marianan, Meric‐Bernstam, Funda, Buchholz, Thomas A., Sahin, Aysegul, Do, Kim‐Anh, Hortobagyi, Gabriel N., Gonzalez‐Angulo, Ana M.

“…PURPOSE: To evaluate the impact of low estrogen/progesterone receptor (ER/PR) expression and effect of endocrine therapy on survival outcomes in human…”
Get full text

Sea Shells And Natural Fibres Composites: A Review by Vijaya Ramnath, B., Jeykrishnan, J., Ramakrishnan, G., Barath, B., Ejoelavendhan, E., Arun raghav, P.

“…The main aim of this work is to study the mechanical and chemical properties of the known mollusc shells like periwinkles, clams, land snails, green oysters,…”
Get full text

Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older by Mizrahi, Jonathan D., Rogers, Jane E., Hess, Kenneth R., Wolff, Robert A., Varadhachary, Gauri R., Javle, Milind M., Shroff, Rachna T., Ho, Linus, Fogelman, David R., Raghav, Kanwal P.S., Overman, Michael J., Pant, Shubham

“…Although FOLFIRINOX (5-Fluorouracil + leucovorin + irinotecan + oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer…”
Get full text

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations by Piha-Paul, Sarina A., Tseng, Chieh, Leung, Cheuk Hong, Yuan, Ying, Karp, Daniel D., Subbiah, Vivek, Hong, David, Fu, Siqing, Naing, Aung, Rodon, Jordi, Javle, Milind, Ajani, Jaffer A., Raghav, Kanwal P., Somaiah, Neeta, Mills, Gordon B., Tsimberidou, Apostolia M., Zheng, Xiaofeng, Chen, Ken, Meric-Bernstam, Funda

“…Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage…”
Get full text

Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach by Vega, Eduardo A., Yamashita, Suguru, Shin, Chun Yun, Kim, Michael, Fleming, Jason B., Katz, Mathew H., Raghav, Kanwal P. S., Vauthey, Jean-Nicolas, Lee, Jeffrey E., Conrad, Claudius

“…Background Laparoscopic partial splenectomy (LPS) for focal splenic lesions is technically demanding and carries risk of hemorrhage. Nevertheless, it can be a…”
Get full text

Investigating the efficacy of an interactive warning for use in labeling strategies used by us pharmacies by Lee, Jiyon, Ladoni, Moslem, Richardson, James, Sundar, Raghav P., Bix, Laura

“…Abstract Background: United States pharmacies repackage medications into multi-dose vials, enabling customized dosing for prescription drugs. Investment in…”
Get full text

Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas by Raghav, Kanwal P.S., Shetty, Aditya V., Kazmi, Syed M.A., Zhang, Nianxiang, Morris, Jeffrey, Taggart, Melissa, Fournier, Keith, Royal, Richard, Mansfield, Paul, Eng, Cathy, Wolff, Robert A., Overman, Michael J.

“…Background. Appendiceal adenocarcinomas (AAs) are rare and this has limited their molecular understanding. The purpose of our study was to characterize the…”
Get full text

Molecular identification of beta lactamase producing gram negative bacteria in water samples collected from River Yamuna in Agra Region by Kumar, A, Asthana, M, Sharma, R, Amdekar, S, Raghav, P, katoch, M, Katoch, V.M

Get full text

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma by Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia

“…Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of…”
Get full text

Molecular Pathways and Mechanisms of HER2 in Cancer Therapy by Raghav, Kanwal P S, Moasser, Mark M

“…The oncogene ERBB2 encoding the receptor tyrosine-protein kinase erbB-2 (HER2) is frequently overexpressed or amplified and occasionally mutated in a variety…”
Get full text

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room by Raghav, Kanwal P S, Loree, Jonathan M, Kopetz, Scott

“…Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive…”
Get full text

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) by Kopetz, Scott, Guthrie, Katherine A, Morris, Van K, Lenz, Heinz-Josef, Magliocco, Anthony M, Maru, Dipen, Yan, Yibing, Lanman, Richard, Manyam, Ganiraju, Hong, David S, Sorokin, Alexey, Atreya, Chloe E, Diaz, Luis A, Allegra, Carmen, Raghav, Kanwal P, Wang, Stephen E, Lieu, Christopher H, McDonough, Shannon L, Philip, Philip A, Hochster, Howard S

“…mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of by…”
Get full text

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors by Ludford, Kaysia, Ho, Won Jin, Thomas, Jane V, Raghav, Kanwal P S, Murphy, Mariela Blum, Fleming, Nicole D, Lee, Michael S, Smaglo, Brandon G, You, Y Nancy, Tillman, Matthew M, Kamiya-Matsuoka, Carlos, Thirumurthi, Selvi, Messick, Craig, Johnson, Benny, Vilar, Eduardo, Dasari, Arvind, Shin, Sarah, Hernandez, Alexei, Yuan, Xuan, Yang, Hongqui, Foo, Wai Chin, Qiao, Wei, Maru, Dipen, Kopetz, Scott, Overman, Michael J

“…Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid…”
Get full text